Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Effect of Pomegranate Extract Intake on Body Composition and Blood Pressure.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02017132
Recruitment Status : Unknown
Verified December 2013 by Angela Stockton, Queen Margaret University.
Recruitment status was:  Active, not recruiting
First Posted : December 20, 2013
Last Update Posted : December 20, 2013
Information provided by (Responsible Party):
Angela Stockton, Queen Margaret University

Brief Summary:

Pomegranate has gained widespread popularity since the health effects of the whole fruit, as well as its juices and extracts, have been studied in relation to a variety of chronic conditions such as hypertension, diabetes, obesity, cancer and cardiovascular disease.

The fruit consists of peel, seeds and berries or arils. The peel is rich in minerals and compounds such as polyphenols, but is not an edible part of the plant. In order to harness the benefits of all parts of the fruit, the whole fruit can be crushed and powdered and then easily consumed as pomegranate extract capsules.

Pomegranate has been shown to be effective at reducing cardiovascular disease risk factors, particularly with respect to decreasing blood pressure and increasing insulin sensitivity. Dietary polyphenols may also suppress body fat growth. Recently, positive effects on fat reduction have been shown using pomegranate and its extracts. In animal models it has been shown for both extract and leaf that there were significant decrease in food consumption and body weight, inhibiting the development of obesity. In the few human studies, there appeared to be a trend towards a reduction in waist circumference and fat mass, plus a halt in body weight increase, for both juice and seed oil.

This parallel, double blinded, randomised, placebo controlled trial aims to confirm previous results concerning the effect of whole pomegranate fruit on biochemical and physiological markers using a new pomegranate extract and to conduct original work to explore its effect on body weight, measurements and fat mass. Any similar interventions have not been double blinded or used pomegranate in extract form. Changes in physiological and biochemical markers will also be investigated.

The study hypothesis is that pomegranate extract will reduce BMI and body weight, fat mass, body measurements and blood pressure.

Condition or disease Intervention/treatment Phase
Obesity Diabetes Cardiovascular Disease Dietary Supplement: Pomegranate extract Not Applicable

Detailed Description:

This is a parallel, double blinded, placebo controlled, randomised trial. It will be conducted over an 8 week intervention phase, plus a pre-intervention registration and preparation period. Participants will be randomly assigned to either the pomegranate extract or placebo groups. One capsule of Pomegranate or placebo will be taken after the same time daily meal with water for 8 weeks.

Participants will be asked to visit the clinical lab three times. The first visit will be for baseline measurements and a 24 hour urine sample before the intervention begins; the second in week 4 for measurements only and the final visit in week 8 for measurements and the last urine collection. Blood pressure and anthropometric measurements will be taken at each visit. Urine will only be collected pre and post intervention.

The health related Quality of Life Questionnaire (Rand 36) will be administered at both the initial and final visits. This series of questions covers eight spheres of health and has been proven to be scientifically robust having been used in over 200 health related scientific trials.

Three day diet diaries will be used for recording energy intake and to determine any fluctuations in dietary intake over the study period. These will be completed by participants in the pre-intervention week and then at week 4 of the intervention. Participants complete 2 diet diaries in total.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 55 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: The Effect of Pomegranate Extract on Anthropometric, Physiological and Biochemical Parameters in Human Volunteers: an 8 Week Parallel, Double Blinded, Placebo Controlled, Randomised Trial.
Study Start Date : April 2013
Estimated Primary Completion Date : December 2013
Estimated Study Completion Date : January 2014

Arm Intervention/treatment
Active Comparator: Pomegranate extract
1.1g pomegranate extract capsule administered daily to each participant for 8 weeks
Dietary Supplement: Pomegranate extract
Other Name: Pomegreat PurePlus

Placebo Comparator: Placebo capsule
1.1g placebo capsule taken daily by each participant for 8 weeks

Primary Outcome Measures :
  1. Changes in measurements of body mass indicators [ Time Frame: Week 0, 4, 8 ]

    These indicators are:

    Body weight; height; BMI; waist, hip and mid-upper arm circumference; fat and fat free mass.

Secondary Outcome Measures :
  1. Changes in blood pressure [ Time Frame: Week 0, 4, 8 ]
    Systolic and diastolic blood pressure are taken when volunteers are supine

Other Outcome Measures:
  1. Changes in Quality of life [ Time Frame: Week 0, 8 ]
    Administered through the Rand 36 questionnaire

  2. Changes in urinary polyphenol and FRAP levels [ Time Frame: Week 0, 8 ]
    Measured using the 24hr urine collection

  3. Change in urinary cortisol-to-cortisone ratio [ Time Frame: Week 0, 8 ]
    Determined via the 24hr urine collection

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy volunteers with a BMI within the range of 18-34.9 kg/m².

Exclusion Criteria:

  • Taking medications for heart, liver or kidney disease, or diabetes;
  • recent weight loss within 2 months preceding the study;
  • pregnancy;
  • lactation;
  • allergies to pomegranate.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02017132

Layout table for location information
United Kingdom
Queen Margaret University
Musselburgh, Edinburgh, United Kingdom, EH21 6UU
Sponsors and Collaborators
Queen Margaret University
Layout table for investigator information
Principal Investigator: Angela EV Stockton, MSc Queen Margaret University
Layout table for additonal information
Responsible Party: Angela Stockton, Ph.D. Researcher, Queen Margaret University Identifier: NCT02017132    
Other Study ID Numbers: POM-02Extr
First Posted: December 20, 2013    Key Record Dates
Last Update Posted: December 20, 2013
Last Verified: December 2013
Keywords provided by Angela Stockton, Queen Margaret University:
Blood pressure
Body composition
Fat mass
Quality of Life
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases